Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00812188|
Recruitment Status : Completed
First Posted : December 22, 2008
Last Update Posted : February 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Symmetric Limited Morphea||Other: Medium Dose UVA-1 Other: High Dose UVA-1||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea|
|Study Start Date :||November 2004|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||November 2009|
Active Comparator: Medium Dose UVA-1
Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
Other: Medium Dose UVA-1
UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
Active Comparator: High Dose UVA-1
High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
Other: High Dose UVA-1
High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
- Efficacy of UVA-1 treatment vs. topical steroid. [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00812188
|United States, Texas|
|UT Southwestern Medical Center at Dallas - Department of Dermatology Clinical Trials|
|Dallas, Texas, United States, 75390|
|Principal Investigator:||Heidi Jacobe, M.D.||UT Southwestern Medical Center at Dallas|